A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia
Identifieur interne : 002494 ( Main/Exploration ); précédent : 002493; suivant : 002495A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia
Auteurs : Donald C. Goff [États-Unis] ; Perry F. Renshaw [États-Unis] ; Ofra Sarid-Segal [États-Unis] ; Daniel A. Dreyfuss [États-Unis] ; Edward T. Amico [États-Unis] ; Domenic A. Ciraulo [États-Unis]Source :
- Biological Psychiatry [ 0006-3223 ] ; 1992.
Abstract
The goal of this study was to determine whether selegiline (l-deprenyl), a selective monoamine oxidase B inhibitor and antioxidant, would improve neuroleptic-induced tardive dyskinesia (TD). Thirty-three patients with TD were randomly assigned to selegiline 10 mg/day or placebo for 6 weeks and were assessed at baseline and at weeks 1, 2, 4, and 6 for TD, parkinsonism, akathisia, depression, and positive and negative symptoms. Examinations for TD were videotaped and scored by a rater unaware of the temporal sequence of examination. Twenty-eight subjects completed at least 1 week of treatment; all five dropouts were receiving selegiline. When baseline score and gender were controlled, the group receiving selegiline displayed significantly less improvement of TD compared with the placebo group. The two treatment groups did not differ in any other outcome measure. Selegiline was less effective than placebo in reducing symptoms of TD over a 6-week trial. This may be the result of the dopamine agonist effects associated with selegiline.
Url:
DOI: 10.1016/0006-3223(93)90119-X
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia</title><author><name sortKey="Goff, Donald C" sort="Goff, Donald C" uniqKey="Goff D" first="Donald C." last="Goff">Donald C. Goff</name></author><author><name sortKey="Renshaw, Perry F" sort="Renshaw, Perry F" uniqKey="Renshaw P" first="Perry F." last="Renshaw">Perry F. Renshaw</name></author><author><name sortKey="Sarid Segal, Ofra" sort="Sarid Segal, Ofra" uniqKey="Sarid Segal O" first="Ofra" last="Sarid-Segal">Ofra Sarid-Segal</name></author><author><name sortKey="Dreyfuss, Daniel A" sort="Dreyfuss, Daniel A" uniqKey="Dreyfuss D" first="Daniel A." last="Dreyfuss">Daniel A. Dreyfuss</name></author><author><name sortKey="Amico, Edward T" sort="Amico, Edward T" uniqKey="Amico E" first="Edward T." last="Amico">Edward T. Amico</name></author><author><name sortKey="Ciraulo, Domenic A" sort="Ciraulo, Domenic A" uniqKey="Ciraulo D" first="Domenic A." last="Ciraulo">Domenic A. Ciraulo</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5B9536204B4930DE374E3F937DF6F8F5C9FC1866</idno><date when="1993" year="1993">1993</date><idno type="doi">10.1016/0006-3223(93)90119-X</idno><idno type="url">https://api.istex.fr/document/5B9536204B4930DE374E3F937DF6F8F5C9FC1866/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">003085</idno><idno type="wicri:Area/Main/Curation">002C90</idno><idno type="wicri:Area/Main/Exploration">002494</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia</title><author><name sortKey="Goff, Donald C" sort="Goff, Donald C" uniqKey="Goff D" first="Donald C." last="Goff">Donald C. Goff</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Renshaw, Perry F" sort="Renshaw, Perry F" uniqKey="Renshaw P" first="Perry F." last="Renshaw">Perry F. Renshaw</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Sarid Segal, Ofra" sort="Sarid Segal, Ofra" uniqKey="Sarid Segal O" first="Ofra" last="Sarid-Segal">Ofra Sarid-Segal</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Dreyfuss, Daniel A" sort="Dreyfuss, Daniel A" uniqKey="Dreyfuss D" first="Daniel A." last="Dreyfuss">Daniel A. Dreyfuss</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Amico, Edward T" sort="Amico, Edward T" uniqKey="Amico E" first="Edward T." last="Amico">Edward T. Amico</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Ciraulo, Domenic A" sort="Ciraulo, Domenic A" uniqKey="Ciraulo D" first="Domenic A." last="Ciraulo">Domenic A. Ciraulo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>From the Erich Lindermann Mental Health Center, the Psychiatry Service of the Massachusetts General Hospital, Harvard Medical School; and the Boston VA Outpatient Clinic and Tufts School of Medicine, Boston, MA</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Biological Psychiatry</title><title level="j" type="abbrev">BPS</title><idno type="ISSN">0006-3223</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1992">1992</date><biblScope unit="volume">33</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="700">700</biblScope><biblScope unit="page" to="706">706</biblScope></imprint><idno type="ISSN">0006-3223</idno></series><idno type="istex">5B9536204B4930DE374E3F937DF6F8F5C9FC1866</idno><idno type="DOI">10.1016/0006-3223(93)90119-X</idno><idno type="PII">0006-3223(93)90119-X</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0006-3223</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The goal of this study was to determine whether selegiline (l-deprenyl), a selective monoamine oxidase B inhibitor and antioxidant, would improve neuroleptic-induced tardive dyskinesia (TD). Thirty-three patients with TD were randomly assigned to selegiline 10 mg/day or placebo for 6 weeks and were assessed at baseline and at weeks 1, 2, 4, and 6 for TD, parkinsonism, akathisia, depression, and positive and negative symptoms. Examinations for TD were videotaped and scored by a rater unaware of the temporal sequence of examination. Twenty-eight subjects completed at least 1 week of treatment; all five dropouts were receiving selegiline. When baseline score and gender were controlled, the group receiving selegiline displayed significantly less improvement of TD compared with the placebo group. The two treatment groups did not differ in any other outcome measure. Selegiline was less effective than placebo in reducing symptoms of TD over a 6-week trial. This may be the result of the dopamine agonist effects associated with selegiline.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Goff, Donald C" sort="Goff, Donald C" uniqKey="Goff D" first="Donald C." last="Goff">Donald C. Goff</name></region><name sortKey="Amico, Edward T" sort="Amico, Edward T" uniqKey="Amico E" first="Edward T." last="Amico">Edward T. Amico</name><name sortKey="Ciraulo, Domenic A" sort="Ciraulo, Domenic A" uniqKey="Ciraulo D" first="Domenic A." last="Ciraulo">Domenic A. Ciraulo</name><name sortKey="Dreyfuss, Daniel A" sort="Dreyfuss, Daniel A" uniqKey="Dreyfuss D" first="Daniel A." last="Dreyfuss">Daniel A. Dreyfuss</name><name sortKey="Renshaw, Perry F" sort="Renshaw, Perry F" uniqKey="Renshaw P" first="Perry F." last="Renshaw">Perry F. Renshaw</name><name sortKey="Sarid Segal, Ofra" sort="Sarid Segal, Ofra" uniqKey="Sarid Segal O" first="Ofra" last="Sarid-Segal">Ofra Sarid-Segal</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002494 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002494 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5B9536204B4930DE374E3F937DF6F8F5C9FC1866
|texte= A placebo-controlled trial of selegiline (l-deprenyl) in the treatment of tardive dyskinesia
}}
| This area was generated with Dilib version V0.6.23. |  |